Spinogenix Announces Publication of Preclinical Study Demonstrating Neuroprotective Effects of SPG302 in a Model of Glaucoma

The Study Results, Published in Experimental Eye Research journal, Found SPG302 Protected Retinal Ganglion Cells and Their Axons in the Glaucomatous Retina and Improved Retinal Function LOS ANGELES, Oct. 16, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company...